Rappta Therapeutics

Investment area
Novo Seeds
Region
Europe
Date of investment
August 2020

Rappta Therapeutics is working on a first-in-class series of anti-cancer molecules that reactivate a key tumor suppressor, protein phosphatase 2A (PP2A). Rappta’s proprietary tools and understanding of the target allow them to therapeutically reactivate PP2A, a critical enzyme regulating protein de-phosphorylation and tumor growth. As a result of PP2A’s central role in the regulation of protein phosphorylation, Rappta’s PP2A-reactivating technologies have platform potential in human therapeutic use.

Rappta Therapeutics

Investment area
Novo Seeds
Region
Europe
Date of investment
August 2020

Rappta Therapeutics is working on a first-in-class series of anti-cancer molecules that reactivate a key tumor suppressor, protein phosphatase 2A (PP2A). Rappta’s proprietary tools and understanding of the target allow them to therapeutically reactivate PP2A, a critical enzyme regulating protein de-phosphorylation and tumor growth. As a result of PP2A’s central role in the regulation of protein phosphorylation, Rappta’s PP2A-reactivating technologies have platform potential in human therapeutic use.

Rappta Therapeutics

Investment area
Novo Seeds
Region
Europe
Date of investment
August 2020

Rappta Therapeutics is working on a first-in-class series of anti-cancer molecules that reactivate a key tumor suppressor, protein phosphatase 2A (PP2A). Rappta’s proprietary tools and understanding of the target allow them to therapeutically reactivate PP2A, a critical enzyme regulating protein de-phosphorylation and tumor growth. As a result of PP2A’s central role in the regulation of protein phosphorylation, Rappta’s PP2A-reactivating technologies have platform potential in human therapeutic use.